Long’n Lean ® is a training technique designed to enrich your life with the benefits derived from muscle flexibility and good body posture. The exercises combine structure from yoga and graceful dance stretches in a setting that enhances relaxation. Flexibility training provides many important benefits that cannot beachieved by any other exercise or activity. Try also the fun, advanced Pop Yoga-class with kicks, splits and twists! This is a flow class – a real energizer and work out!

Ose Water AS is a Norwegian bottled water and bag-in-box water producer.The water source is Ose which provides high quality natural mineral water. The company aim to be in production for international sale in Q1 2019. Ose Water AS is a producer of natural mineral water from the Ose spring in Bygland municipality, Aust-Agder county in Norway.

Secure Payment Transaction System with #1 Ranking Our App is integrated with the most secure payment gateways in the world. We use the most advanced encryption technology to ensure that your payment is safe and secure. We are the first to integrate local banks directly with < 1% transaction fee thanks to PSD2 License ( Card-Less Transactional Handshake )

Bookify is a nationwide search portal targeted to anyone planning meetings, events, conferences, kick-offs, and much more. With different search criteria and filters, you`ll have simple access to meetings and conference venues adapted to your standards. Quick and Easy. Bookify makes it easy to find meeting rooms, function rooms and conference rooms. We also simplify the process for people who have a suitable premise they want to rent out but do not know how to proceed. In the app you can quickly find premises near you, it is easy to find the premises that have the facilities you are looking for and payment is done seamlessly right in the app! The app uses geolocation so that you can quickly book the premises you are looking for. At the same time, you can also do more advanced searches to book ahead of time. You have a full overview of upcoming meeting rooms, payment history and receipt archives. In addition, you can add premises you use often as favorites to make the booking process even easier and faster!

The Founder Institute is the world’s premier startup launch program for talented entrepreneurs. If you are up to the challenge, our comprehensive step-by-step program will give you the structure, mentor support, and network of entrepreneurs you need to start an enduring company. Based in Silicon Valley and with chapters across 60 countries, the Founder Institute's mission is to "Globalize Silicon Valley" and build sustainable startup ecosystems worldwide.

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Our mission is to create a thriving and evolving community of startups and creatives.DIGS is an innovation platform located in Trondheim, built on exchanges between members and partners who unite entrepreneurs, ‘makers’, and ‘doers’ from varied sectors. DIGS supports startup activities by providing an office environment and space for public activities, stimulating a culture of collaboration, sustainability, and mutual innovation through shared knowledge and experience. We participate in entrepreneurship networks across Norway, Europe, and internationally and aim to strengthen ties, stimulate the local community, and boost business development in and around the region of Trondheim. The idea of creating DIGS started with three enthusiastic people who wanted to make space for innovation in Trondheim. They started working on the idea in 2011 and acquired the space we are currently located in in the summer of 2013. The word DIGS means workplace and living space.

We democratize e-commerce! We wish to make the process of selling and making money online available to everyone! Most of our users have never run an online store before, and we know that! That is why we have developed a solution that is so easy to use that anyone can set up and launch their own online store in just a few minutes. Yes, even you!

Defigo is the only intelligent building system designed for apartment buildings. We plug into the building infrastructure, control door locks, elevators, lights, ventilation, and fire alarms, and provide users with one common user interface. We offer a wide range of intelligent and innovative services, provided by ourselves or through partners, that increase safety and convenience and reduce cost and hassle.

We’re an independent game studio based in Oslo, Norway, which was founded in February 2013 by a group of students at the Norwegian School of Information Technology (NITH). In January 2014 we consisted of 7 members of the team who all have different experiences in their own fields of expertise. Our common goal is that we want to contribute to the indie scene with story-driven games, without compromising the gameplay. Starting up a new company (let alone within gaming) is no joke, and we hope to make it easier for future companies to make games. It’s a small pond, and as soon as we announce our projects, our vision is to have an exposed development during production. So keep an eye on our development blog on our page, or contact us if you want to know anything! We are currently working on a third-person horror game, set in a forest inspired by Norwegian nature.

Nordic Gelato Factory is producing beatiful vegan gelato. It is all hand-made, sustainable, locally produced Italian style ice-cream. We have proven sales data from Finland and customer testimonials are overwhelmingly good. At the moment we are entering Danish market. We have been looking for right investor but we are still on process to finding the suitable. But in order to meet to requirement fo funding we need more skilful people onboard. Since we are not aiming to be only ice-cream shop in traditional context but a supplier for Gelato as a Service business model we need different knowledge onboard in order to execute the plan. This business model would need knowledge how to run a subscription model as well as handling the logistics. Lean production planning is crucial for effective production runs. Our marketing strategy wil be outsourced and we have the right company to do it. And extra pair of hands is needed for day-to-day marketing updates ! I am the company owner and founder. My best skill are in sales and marketing as well as creating customer experience. I can run the production as well. For the operational team we would need 2-4 persons with different talents supporting the journey of Nordic Gelato Factory. After getting Denmark up and running we are heading to LONDON!

Pentonet are an established startup providing data and communication service solutions to the maritime industry. The connectivity of people and devices on boards ships is our business. Very simply we provide smarter communications for ships and sailors. The primary services that we supply are: 1. Near Shore LTE services providing a ship to shore data link based on our own LTE router that has global support, end to end firmware management and a host of special remote access features and management 2. Global Mobile service SIM cards aimed at sailors who travel constantly. 3. Onboard VoIP services for business and crew using our own platform and global reach partners fro allow us to supply multinational DIDs.

Themsen Health ApS - Denmark's leader in Nitrile gloves Themsen Health ApS helps companies with nitrile gloves of the highest quality. Directly from one of the world's leading manufacturers to the customer without expensive intermediaries. At Themsen Health ApS, the health and safety of our partners and customers is the first priority. Credibility, quality and safety are our core values, which are reflected in our products and organization. We therefore guarantee to supply 100% approved nitrile gloves that are quality assured and approved by the EU and the Danish Health Authority's guidelines. Our mission is to ensure that your company can create the best framework for a hygienic, clean and safe workplace for your employees.